Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference
Nuvalent (Nasdaq: NUVL) said CEO James Porter, Ph.D., and CFO Alexandra Balcom will take part in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 8:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nuvalent (Nasdaq: NUVL) said CEO James Porter, Ph.D., and CFO Alexandra Balcom will take part in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 8:30 a.m. ET. A live webcast will be available in the Investors section of the company's website and will be archived for 30 days after the presentation.
Details
News Market Reaction – NUVL
On Nov 26, the day this news came out, NUVL closed 0.73% below the previous close.
Data tracked by StockTitan Argus for the Nov 26 session.
Key Figures
- Conference edition
- 37th Annual
- Piper Sandler Healthcare Conference
- Event time
- December 4, 2025 at 8:30 a.m. ET
- Scheduled fireside chat
- Webcast archive length
- 30 days
- Duration webcast will remain available to investors
Historical Context
-
Announcement of fireside chat at Piper Sandler healthcare conference.
-
Closing of underwritten offering and full exercise of over-allotment option.
-
FDA acceptance of NDA for zidesamtinib with a set PDUFA date.
-
Pricing of public offering of common stock at $101.00 per share.
-
Announcement of planned $500.0 million underwritten equity offering.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference-302626096.html
SOURCE Nuvalent, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.